Proportion of people requiring non‐invasive ventilation · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether intravenous magnesium sulfate + standard care changes proportion of people requiring non‐invasive ventilation compared with placebo + standard care (very low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Length of hospital stay · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in oxygen saturation (SaO2) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Proportion of people with hospital admissions (from the emergency room) · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether nebulised magnesium sulfate + standard care changes proportion of people with hospital admissions (from the emergency… compared with placebo + standard care (very low certainty).
1 finding from 1 review
Incidence of admissions to the ICU · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether nebulised magnesium sulfate + standard care changes proportion of people requiring ICU admission compared with placebo + standard care (very low certainty).
1 finding from 1 review
Tinnitus symptom severity · adults with tinnitus
1 finding from 1 review
Serious adverse effects (bleeding or seizures) · adults with tinnitus
1 finding from 1 review
Tinnitus loudness · adults with tinnitus
1 finding from 1 review
Health‐related quality of life · adults with tinnitus
1 finding from 1 review
Other adverse effects (gastrointestinal upset, headache, allergic reaction) · adults with tinnitus
Ginkgo biloba showed no clear difference in other adverse effects (gastrointestinal upset, headache, allergic… compared with placebo (low certainty).
1 finding from 1 review
Pain score · women having medical abortion before 14 weeks' gestation
1 finding from 1 review
Nausea · women having medical abortion before 14 weeks' gestation
Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (nausea) compared with placebo (low certainty).
1 finding from 1 review
Vomiting · women having medical abortion before 14 weeks' gestation
Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (vomiting) compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · women having medical abortion before 14 weeks' gestation
Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (diarrhoea) compared with placebo (low certainty).
1 finding from 1 review
Complete abortion rate ‐ not reported · women having medical abortion before 14 weeks' gestation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found